Novartis Forecasts 8% Sales Growth for 2025 and Announces $3 Billion Acquisition

Novartis has announced a positive outlook for 2025, projecting an 8% increase in full-year sales to reach approximately $54.53 billion. To bolster its long-term growth, the pharmaceutical giant entered into a $3 billion agreement to acquire Synnovation Therapeutics. This strategic move is specifically designed to strengthen the company’s oncology pipeline, focusing on HR+/HER2- breast cancer treatments. The acquisition comes as Novartis prepares for significant patent expirations in 2026 for its key drugs Entresto, Promacta, and Tasigna. Analysts view the proactive M&A strategy as a vital step to offset projected revenue losses from these upcoming patent cliffs. Overall, the strong sales guidance and strategic expansion provide a bullish signal for investors despite the known long-term headwinds.

Sources:seekingalpha.comtradingview.comzacks.comstocktitan.netinvesting.comfiercepharma.comstockinvest.usdirectorstalkinterviews.commmm-online.com